Drug Trial Radar · NCT03860272
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
499
Actual
Start
Mar 20, 2019
Primary completion
Jan 13, 2025
Study completion Dec 2027
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D) of botensilimab monotherapy and in combination with balstilimab.
Conditions
- Advanced Cancer
- Angiosarcoma
- Colorectal Cancer Without Liver Metastases
- Endometrial Cancer
- Fibrolamellar Carcinoma
- Non-small-cell Lung Cancer
- Ovarian Cancer
- Prostate Cancer
Interventions
BotensilimabDrug
An Fc-engineered anti-CTLA-4 monoclonal antibody
BalstilimabDrug
A fully human monoclonal anti-PD-1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Of Treatment-emergent Adverse Events (TEAEs)Time frame: First dose through 90 days following last study dose (up to 2 years)
- DLT Of BotensilimabTime frame: First 28 days of treatment
- RP2D Of BotensilimabTime frame: First dose through 90 days following last study dose
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
City of Hope Comprehensive Cancer Center
Duarte, California
The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate
Los Angeles, California
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California
UCLA Santa Monica Hematology Oncology
Los Angeles, California
Saint John's Cancer Institute
Santa Monica, California
University of Colorado
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Providence Portland Cancer Center
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
The University of Texas Health Science Center at San Antonio
San Antonio, Texas
Royal Marsden Hospital NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.